Compare Okta, Inc. (OKTA) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Okta, Inc. vs 10X Genomics Inc — how do they compare? Okta, Inc. trades at $226.43 (market cap $38.50B), while 10X Genomics Inc trades at $82 (market cap $10.07B). The key difference: Okta, Inc. is far larger — about 3.8× 10X Genomics Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Okta, Inc. for 44 Days and 10X Genomics Inc for 92 Days on average.
| OKTA | TXG | |
|---|---|---|
Market Cap | $38.50B | $10.07B |
Volume | 2,479,621 | 5,657,286 |
Sector | Technology | Health |
52-Week High | $220.21 | $97.74 |
52-Week Low | $62.93 | $11.48 |
Typical Hold Time | 44 Days | 92 Days |
Enterprise Value | $36.25B | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKTA trades at $218.00, down slightly by 0.31% on the day, with a bullish technical signal from moving averages and strong quarterly earnings beats. The company reported a net income of $28 million in 2025, marking a significant turnaround from previous losses, while revenue grew to $2.61 billion. Recent news highlights its AI agent security initiatives, including the Blueprint Alliance unveiled at Oktane 2026.
Outlook remains positive with robust analyst support (73.58% buy ratings) and a consensus price target of $201.30, though high valuation ratios and overbought RSI readings pose near-term risks. Long-term growth is supported by identity management demand and AI positioning, but competition and execution challenges are key investor considerations.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
